Developer docs
API playgroundTry for free, no card

Search company profiles

Cerus Endovascular

Full company profile

uuid000b5p7

Namestring
Cerus Endovascular
Websiteurl
cerusendo.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Cerus Endovascular is a privately held, for-profit medical device company founded in 2011 and headquartered in Oxford, United Kingdom. The company designs and develops interventional neuroradiology devices and delivery systems, targeting the neurovascular intervention market where clinicians treat intracranial aneurysms, stroke, and other cerebrovascular conditions using catheter-based approaches.

The company's product offering centers on the engineering of specialty implants and the catheter-based delivery systems used to deploy them inside the cerebral vasculature. Operating with a micro-cap headcount of 1-10 employees, the company is positioned at the early-stage development phase typical of pre-commercial neurovascular startups, with R&D, design, and prototyping as its core functions. No specific product SKUs, FDA/CE mark filings, clinical trial data, or named reference customers are disclosed in the available material.

Cerus Endovascular's business model is consistent with early-stage medical device commercialization: it has historically funded operations through equity capital — a 2013 seed round of approximately $2.33 million from Mid Atlantic Bio Angels and The North West Fund, followed by an undisclosed second round in February 2020 — and is presumed to be pursuing a pathway of regulatory clearance (FDA/CE mark) and either direct sales or licensing/distribution partnerships with larger neurovascular players (e.g., Stryker, Medtronic, MicroVention, Penumbra) once approvals are obtained. The company has no disclosed revenue, publicly disclosed pricing, or named end customers in the current dataset.

Short descriptiontext

Cerus Endovascular is a privately held Oxford-based medical device company founded in 2011 that designs and develops interventional neuroradiology devices and delivery systems for the treatment of cerebrovascular conditions.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersOxford, United Kingdom
HQ citystring
Oxford
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
interventional neuroradiology, neurovascular medical devices, cerebral aneurysm treatment, intracranial delivery systems, embolization devices
Industry2 codes
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAEAD
Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
NAICS code1 code
  • Surgical and Medical Instrument Manufacturing339112
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Neurovascular Medical Devices
Social media profiles1 record
Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Cerus Endovascular designs and develops interventional neuroradiology devices and delivery systems used in the treatment of cerebral aneurysms and other neurovascular conditions. The company's core focus is on the engineering of specialised implants and the delivery platforms that deploy them within intracranial vasculature.

Differentiator
Functional benefit
Problem solved
Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
1Penumbra
TypeDirect peer
Description

Penumbra is a leading neurovascular and peripheral vascular device company whose stroke/thrombectomy portfolio directly competes with Cerus Endovascular's interventional neuroradiology focus. Both target mechanical thrombectomy and related neurovascular procedures.

2Stryker Neurovascular
TypeBroad incumbent
Description

Stryker's Neurovascular business (with products like Surpass Elite flow diverter) is a major incumbent in the neurovascular space. Cerus competes with Stryker's neurovascular offerings and aligns with their stated focus on stroke and aneurysm intervention.

3Medtronic Neurovascular
TypeBroad incumbent
Description

Medtronic's Neurovascular franchise spans coils, flow diversion, and access devices used in interventional neuroradiology. It is a broad incumbent competing in the same procedure categories as Cerus Endovascular.

4Terumo Neuro (MicroVention)
TypeDirect peer
Description

Terumo Neuro (formerly MicroVention) develops coils, flow diverters, and access devices for interventional neuroradiology — a directly comparable neurovascular device peer targeting the same specialists and procedures as Cerus Endovascular.

5Rapid Medical
TypeEmerging player
Description

Rapid Medical is an emerging neurovascular company developing adjustable stent retrievers and flow diverters, competing directly with Cerus in the interventional neuroradiology device category.

6phenox GmbH
TypeEmerging player
Description

phenox develops flow diverters and implant-assisted devices for intracranial aneurysms and stroke, making it a directly comparable emerging neurovascular device competitor.

7Acandis GmbH
TypeEmerging player
Description

Acandis is a specialist European neurovascular device company developing intracranial implants, flow diverters, and delivery systems — closely comparable to Cerus's interventional neuroradiology devices.

8Balt Group
TypeDirect peer
Description

Balt Group manufactures and distributes interventional neuroradiology products including coils, stents, and access devices, directly overlapping with Cerus Endovascular's device portfolio.

9InspireMD
TypeEmerging player
Description

InspireMD develops neurovascular and carotid scaffold/stent devices for stroke prevention and treatment — an adjacent emerging neurovascular device competitor.

10Cerenovus (Johnson & Johnson MedTech)
TypeBroad incumbent
Description

Cerenovus, J&J's neurovascular business, offers coils, flow diverters, and stroke intervention devices. As a broad incumbent, it competes in the same interventional neuroradiology procedural space as Cerus Endovascular.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cerus Endovascular

Neurovascular Medical Devicescerusendo.com

Cerus Endovascular is a privately held Oxford-based medical device company founded in 2011 that designs and develops interventional neuroradiology devices and delivery systems for the treatment of cerebrovascular conditions.

What Cerus Endovascular does

Cerus Endovascular is a privately held, for-profit medical device company founded in 2011 and headquartered in Oxford, United Kingdom. The company designs and develops interventional neuroradiology devices and delivery systems, targeting the neurovascular intervention market where clinicians treat intracranial aneurysms, stroke, and other cerebrovascular conditions using catheter-based approaches.

The company's product offering centers on the engineering of specialty implants and the catheter-based delivery systems used to deploy them inside the cerebral vasculature. Operating with a micro-cap headcount of 1-10 employees, the company is positioned at the early-stage development phase typical of pre-commercial neurovascular startups, with R&D, design, and prototyping as its core functions. No specific product SKUs, FDA/CE mark filings, clinical trial data, or named reference customers are disclosed in the available material.

Cerus Endovascular's business model is consistent with early-stage medical device commercialization: it has historically funded operations through equity capital — a 2013 seed round of approximately $2.33 million from Mid Atlantic Bio Angels and The North West Fund, followed by an undisclosed second round in February 2020 — and is presumed to be pursuing a pathway of regulatory clearance (FDA/CE mark) and either direct sales or licensing/distribution partnerships with larger neurovascular players (e.g., Stryker, Medtronic, MicroVention, Penumbra) once approvals are obtained. The company has no disclosed revenue, publicly disclosed pricing, or named end customers in the current dataset.

Cerus Endovascular firmographics

Firmographics
Name
Cerus Endovascular
Website
https://cerusendo.com
Company type
Private
Founded year
2011
Headcount range
1–10 employees
Short description
Cerus Endovascular is a privately held Oxford-based medical device company founded in 2011 that designs and develops interventional neuroradiology devices and delivery systems for the treatment of cerebrovascular conditions.
Ownership category
akta.pro rank

Cerus Endovascular industry classification

Industry
Product category
Neurovascular Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAEAD
Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)

Keywords

  • Interventional neuroradiology
  • Neurovascular medical devices
  • Cerebral aneurysm treatment
  • Intracranial delivery systems
  • Embolization devices

Where Cerus Endovascular is headquartered

Location

Headquarters

HQ city
Oxford
HQ country
United Kingdom
HQ region
Europe

Markets served

Cerus Endovascular business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations

Cerus Endovascular product offering

Product offering

Core offering

Cerus Endovascular designs and develops interventional neuroradiology devices and delivery systems used in the treatment of cerebral aneurysms and other neurovascular conditions. The company's core focus is on the engineering of specialised implants and the delivery platforms that deploy them within intracranial vasculature.

Differentiator

Problem solved

Functional benefit

Companies that use Cerus Endovascular

Customer profile

Ideal customer profiles1 record

Cerus Endovascular technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Cerus Endovascular partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights3 records

Cerus Endovascular competitors and assessment

Company assessment

Direct peers

  • Penumbra: Penumbra is a leading neurovascular and peripheral vascular device company whose stroke/thrombectomy portfolio directly competes with Cerus Endovascular's interventional neuroradiology focus. Both target mechanical thrombectomy and related neurovascular procedures.
  • Terumo Neuro (MicroVention): Terumo Neuro (formerly MicroVention) develops coils, flow diverters, and access devices for interventional neuroradiology — a directly comparable neurovascular device peer targeting the same specialists and procedures as Cerus Endovascular.
  • Balt Group: Balt Group manufactures and distributes interventional neuroradiology products including coils, stents, and access devices, directly overlapping with Cerus Endovascular's device portfolio.

Broad incumbents

  • Stryker Neurovascular: Stryker's Neurovascular business (with products like Surpass Elite flow diverter) is a major incumbent in the neurovascular space. Cerus competes with Stryker's neurovascular offerings and aligns with their stated focus on stroke and aneurysm intervention.
  • Medtronic Neurovascular: Medtronic's Neurovascular franchise spans coils, flow diversion, and access devices used in interventional neuroradiology. It is a broad incumbent competing in the same procedure categories as Cerus Endovascular.
  • Cerenovus (Johnson & Johnson MedTech): Cerenovus, J&J's neurovascular business, offers coils, flow diverters, and stroke intervention devices. As a broad incumbent, it competes in the same interventional neuroradiology procedural space as Cerus Endovascular.

Emerging players

  • Rapid Medical: Rapid Medical is an emerging neurovascular company developing adjustable stent retrievers and flow diverters, competing directly with Cerus in the interventional neuroradiology device category.
  • phenox GmbH: phenox develops flow diverters and implant-assisted devices for intracranial aneurysms and stroke, making it a directly comparable emerging neurovascular device competitor.
  • Acandis GmbH: Acandis is a specialist European neurovascular device company developing intracranial implants, flow diverters, and delivery systems — closely comparable to Cerus's interventional neuroradiology devices.
  • InspireMD: InspireMD develops neurovascular and carotid scaffold/stent devices for stroke prevention and treatment — an adjacent emerging neurovascular device competitor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Cerus Endovascular social profiles

Digital presence

Cerus Endovascular financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cerus Endovascular leadership team

Management profile

Number of profiles

Profiles1 record

Cerus Endovascular funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cerus Endovascular M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cerus Endovascular

What does Cerus Endovascular do?

Cerus Endovascular designs and develops interventional neuroradiology devices and delivery systems used in the treatment of cerebral aneurysms and other neurovascular conditions. The company's core focus is on the engineering of specialised implants and the delivery platforms that deploy them within intracranial vasculature.

When was Cerus Endovascular founded?

Cerus Endovascular was founded in 2011. It employs 1 to 10 people.

Where is Cerus Endovascular based?

Cerus Endovascular is headquartered in Oxford, United Kingdom, in the Europe region.

Who are Cerus Endovascular's main competitors?

Direct peers on record are Penumbra, Terumo Neuro (MicroVention) and Balt Group. Broad incumbents are Stryker Neurovascular, Medtronic Neurovascular and Cerenovus (Johnson & Johnson MedTech). Emerging players are Rapid Medical, phenox GmbH, Acandis GmbH and InspireMD.

Does Cerus Endovascular have an API?

No public API is recorded for Cerus Endovascular.

What industry is Cerus Endovascular in?

Cerus Endovascular's product category is Neurovascular Medical Devices. Its primary akta.pro industry code is HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices, with a secondary code of HLAHAEAD, Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireTechnological Advancements and Key Acquisitions Fuel the Aortic Aneurysm Market, Expected to Reach $4.84 Billion by 2027 with a CAGR of 9.21%ResearchAndMarkets.com released its 'Aortic Aneurysm Global Market Report 2023', projecting the market will grow from $3.15 billion in 2022 to $4.84 billion in 2027, representing a compound annual growth rate of 9.21%. The report identifies technological advancements and key acquisitions as prominent market trends, highlighting Stryker Corporation's acquisition of UK-based Cerus Endovascular Ltd. in May 2023 to strengthen its global aneurysm treatment solutions. The increasing prevalence of alcohol and tobacco consumption is cited as a key driver for market growth.BusinessCloudNorth West investor bags 15x return after MedTech saleCerus Endovascular was acquired by Stryker, delivering a 15x return for its North West investor. The deal includes an initial payment to the North West Fund for Biomedical, with further milestone payments expected over two years. The company's products treat brain aneurysms and have been sold in multiple countries.PR NewswireStryker completa l'acquisizione di Cerus EndovascularStryker announced the completion of its acquisition of Cerus Endovascular Ltd., a private medical device company specializing in neurointerventional products for intracranial aneurysms. The deal integrates Cerus's CE-marked Contour Neurovascular System and Neqstent Coil Assisted Flow Diverter into Stryker’s existing portfolio to expand treatment options for endovascular aneurysm therapy.PR NewswireStryker finalise l'acquisition de Cerus EndovascularStryker has completed its acquisition of Cerus Endovascular Ltd., a private medical device company focused on neuro-interventional devices for treating intracranial aneurysms. The deal brings Cerus Endovascular's CE-marked products, the Contour Neurovascular System and the Neqstent Coil Assisted Flow Diverter, into Stryker's aneurysm treatment portfolio, complementing its existing neurovascular offerings. Stryker executives stated the acquisition will enable physicians to treat a broader range of aneurysms and strengthen the company's hemorrhagic portfolio globally.PR NewswireStryker completes acquisition of Cerus EndovascularStryker has completed its acquisition of Cerus Endovascular Ltd., a privately held commercial-stage medical device company focused on neurointerventional devices for treating intracranial aneurysms. The acquired company's CE Marked products, the Contour Neurovascular System and Neqstent Coil Assisted Flow Diverter, will expand Stryker's existing portfolio of aneurysm treatment solutions. The deal is positioned as highly complementary to Stryker's Neurovascular division and is expected to strengthen the company's hemorrhagic portfolio globally.PR NewswireCerus Endovascular Names Stephen Griffin as Chief Executive OfficerCerus Endovascular Ltd. appointed Stephen Griffin, Ph.D. as Chief Executive Officer, effective immediately, succeeding in the role while continuing his existing responsibilities. Dr. Griffin has been with the company since 2014, was appointed President in 2018, and was instrumental in building the company's "Contour" brand internationally and developing its implant product portfolio. The company, which develops interventional neuroradiology devices for treating intracranial aneurysms, expects Dr. Griffin to focus on expanding its global footprint.PR NewswireCerus Endovascular Receives U.S. Food and Drug Administration 510(k) Clearance of its 027 Micro-catheterCerus Endovascular, a privately held commercial-stage medical device company, announced receipt of U.S. FDA 510(k) clearance for its 027 micro-catheters available in two lengths, expanding its existing Contour Neurovascular System platform that already includes the FDA-cleared 021 micro-catheter. The company plans a limited U.S. market release in Q2 2022 and will pursue CE Marking under EU Medical Devices Regulation later this year. Cerus Endovascular is also developing larger Contour system sizes (3mm, 18mm, 22mm) to treat aneurysms up to 18mm in diameter, which it states will address an unmet clinical need for aneurysms 80% larger than current commercially available endo-saccular solutions.PR NewswireCerus Endovascular Receives FDA Breakthrough Device Designation for its Contour Neurovascular System™Cerus Endovascular, a Fremont, California and Oxford, UK-based privately-held medical device company, has received Breakthrough Device Designation from the U.S. FDA for its Contour Neurovascular System™, indicated for treating intracranial aneurysms and already CE Mark-approved with international sales. The designation will expedite the development, assessment, and review process, enabling the company to initiate U.S. clinical trials under an Investigational Device Exemption. The company stated it will work aggressively to bring this innovative device to the U.S. market, where it aims to provide effective, minimally invasive treatment for life-threatening bifurcated intracranial aneurysms.TherobotreportCerus Endovascular announces implant of Contour device with Xcath robotCerus Endovascular announced the first robotically assisted intracranial implant of its Contour device using Xcath's robotic system. The procedure was performed by Dr. Nitin Dange at King Edward Memorial Hospital in Mumbai, India, treating a middle cerebral aneurysm. Company executives described the successful 18-minute operation as a significant milestone for expanding the use of their proprietary neurovascular devices.PR NewswireCerus Endovascular Announces the First Ever Robotic Assist Intracranial Implant of its Contour Intrasaccular DeviceCerus Endovascular Ltd. announced the first ever robotically-assisted intracranial implant of its Contour intrasaccular device, completed at King Edward Memorial Hospital in Mumbai by neurosurgeon Dr. Nitin Dange on a Middle Cerebral Aneurysm patient. The procedure, which used Xcath's microsurgical robotic system, took 28 minutes total including access and device placement. The successful implant represents a technical milestone demonstrating the compatibility of the Contour device with robotic surgical platforms for neurovascular interventions.